Paid Clinical Trials for Prostate Adenocarcinoma

Login to your account

Reset Password

Please Enter Username or Email

Create a free account

I'm a Participant
I'm an Organization

Showing 1 – 20 of 38 results

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

by CTG

in Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC V8, Stage IV Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8

Other

Arizona

Deadline:

12/31/2026

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

by CTG

in Prostate Adenocarcinoma

Other

Illinois

Deadline:

08/30/2028

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

by CTG

in Prostate Adenocarcinoma, Stage IVA Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC V8

Other

Alaska

Deadline:

12/31/2033

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

by CTG

in Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Neoplasm

Other

New Jersey

Deadline:

07/01/2026

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

by CTG

in Prostate Adenocarcinoma, Biochemically Recurrent Prostate Carcinoma

Other

Georgia

Deadline:

04/01/2029

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

by CTG

in Prostate Adenocarcinoma

Other

Maryland

Deadline:

12/01/2026

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

by CTG

in Prostate Cancer, Prostate Adenocarcinoma

Other

Ohio

Deadline:

07/01/2028

CyberKnife Dose Escalation Prostate Cancer Trial

by CTG

in Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm

Other

Pennsylvania

Deadline:

07/12/2028

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

by CTG

in Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Oligometastatic Prostate Carcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma

Other

Arizona

Deadline:

02/01/2029

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

by CTG

in Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Cancer

Other

California

Deadline:

04/30/2026

PSMA PET Imaging of Recurrent Prostate Cancer

by CTG

in Prostate Cancer, Prostate Adenocarcinoma

Other

New Jersey

Deadline:

06/01/2026

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

by CTG

in Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant

Other

Maryland

Deadline:

02/01/2027

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

by CTG

in Prostate Adenocarcinoma

Other

California

Deadline:

04/01/2027

MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

by CTG

in Prostate Cancer, Prostate Adenocarcinoma

Other

Florida

Deadline:

02/13/2028

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

by CTG

in Prostate Adenocarcinoma

Other

Texas

Deadline:

04/30/2026

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

by CTG

in Prostate Adenocarcinoma

Other

Pennsylvania

Deadline:

07/01/2033

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

by CTG

in Prostate Cancer, Prostatic Neoplasms, Prostate Adenocarcinoma

Other

New York

Deadline:

05/01/2027

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients with Prostate Cancer on Active Surveillance

by CTG

in Prostate Cancer, Prostate Adenocarcinoma

Other

California

Deadline:

10/31/2026

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

by CTG

in Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8

Other

Texas

Deadline:

03/30/2026

PSMA PET Response Guided SabR in High Risk Pca

by CTG

in Prostate Adenocarcinoma

Other

Texas

Deadline:

11/01/2026

Load more All clinical trials loaded.